Lifetime treatment costs of β-thalassaemia major
- 24 December 1999
- journal article
- research article
- Published by Wiley in Clinical and Laboratory Haematology
- Vol. 21 (6) , 377-385
- https://doi.org/10.1046/j.1365-2257.1999.00262.x
Abstract
β‐thalassaemia major is a serious genetic disorder, which results in a considerable increase in both acute and chronic morbidity, and mortality. Although β‐thalassaemia major is a rare disease affect...Keywords
This publication has 19 references indexed in Scilit:
- AlcoholismPharmacoEconomics, 1996
- Cost‐effective management of heart failureClinical Cardiology, 1996
- Multicentre study on prevalence of endocrine complications in thalassaemia majorClinical Endocrinology, 1995
- Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults*Clinical Endocrinology, 1995
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Effect of different treatment regimes on linear growth and final height in β‐thalassaemia majorClinical Endocrinology, 1994
- Prevention of heart disease by subcutaneous desferoxamine in patients with thalassaemia majorAustralian and New Zealand Journal of Medicine, 1993
- Transfusion requirements and effects in patients with thalassaemia majorThe Lancet, 1991
- The Cost of DiabetesDiabetic Medicine, 1989